Qinglan (she/her/hers) received her PhD in pharmacology from the University of Houston, where she studied the role of prostaglandins in neurodegeneration using engineered hybrid enzymes to redirect the metabolism of cyclooxygenase pathway. Her postdoctoral training, focusing on developing gene therapies for SURF1 Leigh syndrome, an early onset neurodegenerative mitochondrial disease, was carried out in Dr. Steven Gray’s laboratory at the UT Southwestern Medical Center and was supported by an NIH K99/R00 Pathway to Independence grant from NICHD. 

Qinglan started her independent lab in 2024 at UMass Chan Medical School. Her lab focuses on developing translational gene therapies for mitochondrial diseases. She also enjoys supporting staff and trainees in achieving their career goals. Her main focus as a mentor is for people to learn from her lab and then go on to accomplish even greater things.

When she is not working on science, Qinglan likes to spend time with her dog, Preston.

View LinkedIn